Evidence map›Paper›PMID 42131758›Full record

ReviewNeuro-oncology practice2026

In-hospital costs of malignant brain tumor surgery: A systematic review and quality assessment.

Floor R Pijl, Maik L Landers, Tanvi Kamra, Melissa Kerkhof, Maaike J Vos, Jaap D Zindler, Thijs van Der Vaart, Mar Rodríguez-Girondo, Rob J A Nabuurs, Marike L D Broekman and 4 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neuro-oncology practice, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Floor R PijlDepartment of Neurosurgery,University Neurosurgical Center Holland, Haaglanden Medical Center, The Hague, The Netherlands.ORCID https://orcid.org/0009-0004-7711-2120
Maik L LandersDepartment of Neurosurgery,University Neurosurgical Center Holland, Haaglanden Medical Center, The Hague, The Netherlands.
Tanvi KamraDepartment of Neurosurgery,University Neurosurgical Center Holland, Haaglanden Medical Center, The Hague, The Netherlands.
Melissa KerkhofDepartment of Neurology, Haaglanden Medical Center, The Hague, The Netherlands.
Maaike J VosDepartment of Neurology, Haaglanden Medical Center, The Hague, The Netherlands.
Jaap D ZindlerDepartment of Radiation Oncology, Haaglanden Medical Center, The Hague, The Netherlands (J.D.Z.).
Thijs van Der VaartDepartment of Neurology, Haaglanden Medical Center, The Hague, The Netherlands.
Mar Rodríguez-GirondoDepartment of Medical Statistics, Leiden University Medical Center, Leiden, The Netherlands (M.R.-G.).
Rob J A NabuursDepartment of Neurosurgery,University Neurosurgical Center Holland, Haaglanden Medical Center, The Hague, The Netherlands.
Marike L D BroekmanDepartment of Neurosurgery,University Neurosurgical Center Holland, Haaglanden Medical Center, The Hague, The Netherlands.
Wouter A MoojenDepartment of Neurosurgery,University Neurosurgical Center Holland, Haaglanden Medical Center, The Hague, The Netherlands.
Wilco C PeulDepartment of Neurosurgery,University Neurosurgical Center Holland, Haaglanden Medical Center, The Hague, The Netherlands.
Jeroen T J M van DijckDepartment of Neurosurgery,University Neurosurgical Center Holland, Haaglanden Medical Center, The Hague, The Netherlands.
Rishi D S Nandoe TewarieDepartment of Neurosurgery,University Neurosurgical Center Holland, Haaglanden Medical Center, The Hague, The Netherlands.ORCID https://orcid.org/0000-0003-1697-8428

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The increasing financial burden of therapies for brain tumor patients necessitates strategies that preserve equitable access and optimize resource allocation. The aim of this systematic review was to evaluate the in-hospital costs for malignant brain tumor surgery. A systematic review was carried out according to PRISMA guidelines on January 10, 2025, using the following databases: PubMed, MEDLINE, Embase, Web of Science, Cochrane Library, CENTRAL, CINAHL, PsycINFO, and Academic Search Premier. Articles published after January 1, 2000, describing perioperative hospital costs for malignant brain tumor surgery patients were included. Study quality assessment was performed based on the 2022 CHEERS statement. Nine studies were included, encompassing a total of 140 813 patients. Total in-hospital costs were highly variable and ranged between $2382.47 and $30 836.98 per patient. Mean length of stay (LOS) was 5.24 days, ranging from 3 to 7.12 days. LOS and in-hospital costs were positively correlated. Study quality was low due to missing data on health economic analysis plans, and lack of reporting of uncertainty in the findings. In-hospital costs for malignant brain tumors are high, rising over time, and were significantly impacted by LOS. Study outcomes showed high variability, poor methodological quality due to inconsistent methods and inadequate cost data. Future research needs standardized, comprehensive cost analyses to support informed healthcare policy and resource allocation decisions.

Indexed as

brain tumor surgerycost driversin-hospital costsintracranial malignanciessystematic review

Identifiers

PMID42131758
PMCPMC13161912

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.